Home > Result Summaries: Compounds > GSK1278863 Result Summaries: GSK1278863 GSKStudy ID Phase Title Summary (Download) 112842 phase 1 A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Repeat Oral Doses of 1278863A in Healthy Subjects (0 citation(s)) 112843 phase 1 A Phase I, Single-Dose, Randomized and Single-Blind (Part 1), Fixed Sequence and Open-Label (Part 2), Studyto Evaluate the Safety, Pharmacokinetics, andPharmacodynamics of 1278863A in Subjects with RenalImpairment and Matched Healthy Volunteers (0 citation(s)) 112844 phase 2 A Phase IIa, Randomized, Single-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of 28-day Repeat Oral Doses of GSK1278863A in anemic pre-dialysis and hemodialysis-dependent patients (0 citation(s)) 113634 phase 1 Open Label Study to Assess the Pharmacokinetics of GSK1278863A Coadministered with a High Fat Meal or an Inhibitor of CYP2C8 (gemfibrozil) (0 citation(s)) 114272 phase 2 A multi-center, placebo-controlled study to evaluate the safety and efficacy of GSK1278863 vs. placebo in subjects with peripheral artery disease (PAD). (0 citation(s)) 114703 phase 1 A randomized, open-label, 3-period crossover study in healthy subjects to determine the effect of particle size on the pharmacokinetics of single oral 100mg doses of GSK1278863A (0 citation(s)) 115385 phase 1 A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation (Part 1), fixed Sequence and Open-Label (Part 2), Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects (0 citation(s))
